JOHNSON & JOHNSON |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.4 EUR | -1.73% |
|
-0.07% | -3.46% |
| 07-03 | Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer | MT |
| 07-03 | Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 809B | ||||||
| 624B | ||||||
| 289B | ||||||
| 240B | ||||||
| 220B |
